Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
47.86
+0.24 (0.50%)
At close: Jun 20, 2025, 4:00 PM
47.54
-0.32 (-0.67%)
After-hours: Jun 20, 2025, 7:40 PM EDT
Sanofi Employees
Sanofi had 82,878 employees as of December 31, 2024. The number of employees decreased by 3,210 or -3.73% compared to the previous year.
Employees
82,878
Change (1Y)
-3,210
Growth (1Y)
-3.73%
Revenue / Employee
$589,029
Profits / Employee
$82,148
Market Cap
116.88B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 82,878 | -3,210 | -3.73% |
| Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
| Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
| Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
| Dec 31, 2020 | 99,412 | -997 | -0.99% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
SNY News
- 17 hours ago - BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC - Business Wire
- 1 day ago - Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease - WSJ
- 1 day ago - Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid - GlobeNewsWire
- 2 days ago - RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports - Reuters
- 2 days ago - RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury - CNBC
- 4 days ago - Press release: Sanofi successfully prices €1.5 billion bond issue - GlobeNewsWire
- 4 days ago - SNY Investors Have Opportunity to Join Sanofi Fraud Investigation with the Schall Law Firm - Business Wire
- 5 days ago - Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study - GlobeNewsWire